Sudo raises $147M to advance 2 TYK2 inhibitor therapies to trials multiplesclerosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from multiplesclerosisnewstoday.com Daily Mail and Mail on Sunday newspapers.
The funding will advance two precision TYK2 inhibitors into the clinic for multiple sclerosis, psoriasis and other severe autoimmune and neurologic conditions.New investors include Dementia Discovery Fund, Leaps by Bayer, and UPMC Enterprises.CARMEL, Ind. (BUSINESS WIRE) #TYK2 Sudo Biosciences (“Sudo”), a biophar.